A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

Study Identifier
M25-150
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

Study Details

Medical Condition
  • Healthy Volunteer
  • Study Drug
  • ABBV-722
  • Placebo
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 65 Years

    Protocol Summary

    This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.

    Study Locations

    Location
    Status
    Location
    Acpru /Id# 270279
    Grayslake, Illinois, United States, 60030
    Status
    Recruiting